ArticleVirchows Archiv : an international journal of pathology2025
Can Dedifferentiated Liposarcoma be Reliably Excluded Based on Mitotic Rate? Prognostic and Diagnostic Implications of Mitotic Activity in Liposarcoma.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Distinguishing well-differentiated liposarcoma (WDLPS) from dedifferentiated liposarcoma (DDLPS) is challenging, particularly when the low-grade (LG) sarcoma component does not meet the histopathological criteria for typical DDLPS. Previous studies have suggested that the diagnosis of DDLPS requires at least five mitotic figures per 10 high-power fields (≥ 5/10 HPF). This study aimed to validate the prognostic and diagnostic significance of the mitotic rate in LPS. We retrospectively reviewed 238 cases of WDLPS and DDLPS from our institution and assessed the prognostic value of the mitotic rate, MDM2/CEP12 amplification ratio, and Ki-67 proliferation index. Digital pathology and automated image analysis were used to obtain precise mitotic counts and minimise inter-observer variability. Among 238 patients, 165 had WDLPS, 26 had LG DDLPS, and 47 had DDLPS. LG DDLPS was reclassified when intermediate histological features were observed along with a mitotic rate < 5/10 HPF. Recurrence-free survival (RFS) was significantly worse in LG DDLPS than in WDLPS (P = 0.012) but better than in DDLPS (P = 0.001). Notably, lung metastasis occurred in two (7.7%) of the 26 LG DDLPS cases. The MDM2 amplification ratio progressively increased from WDLPS to DDLPS, whereas the Ki-67 expression level was not significantly associated with prognosis. This study demonstrated that the mitotic rate is a crucial diagnostic and prognostic marker in LPS. LG DDLPS exhibits more aggressive behaviour than WDLPS. Our results suggest that LG DDLPS should not be underestimated or classified as WDLPS based solely on mitotic rate.
Indexed as
Identifiers
40944709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.